JB Capital’s AstraZeneca AZN Stock Holding History

JB Capital’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$21.8M	Buy	+115,025	New	+$21.6M	0.76%	30
2022 Q3	–	Sell	-4,076	Closed	-$539K	–	164
2022 Q2	$539K	Buy	4,076 +71	+2%	+$9.32K	0.06%	148
2022 Q1	$532K	Sell	4,005 -503	-11%	-$60.3K	0.05%	156
2021 Q4	$525K	Buy	4,508 +38	+0.9%	+$4.47K	0.05%	163
2021 Q3	$537K	Buy	+4,470	New	+$520K	0.07%	168

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

JB Capital's AZN Position: Q2 2026 in Review

JB Capital opened a new position in AstraZeneca (AZN) in Q2 2026: 115,025 shares worth $21.8M. The stake represents 0.76% of the portfolio and ranks #30 among its holdings. This is a return to the name: JB Capital previously reported a position in AZN as recently as Q2 2022.

JB Capital first reported a position in AZN in Q3 2021 and has held it in 5 quarters since. 1,502 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

JB Capital held 115,025 shares of AstraZeneca worth $21.8M as of Q2 2026.
AstraZeneca was a new JB Capital position in Q2 2026.
AstraZeneca made up 0.76% of JB Capital's portfolio in Q2 2026, its #30 holding.
JB Capital first reported a position in AstraZeneca in Q3 2021 and has held it in 5 quarters since.
1,502 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on JB Capital's 13F filing for Q2 2026, filed 29 Jul 2026.